

## Ferring – Temporary Discontinuation of Menopur<sup>®</sup> (menotropins for injection)

- On October 24, 2022, Ferring announced the suspension of all shipments of <u>Menopur</u> (<u>menotropins for injection</u>) because of changes made by a third-party supplier in the manufacturing process.
  - The temporary suspension of shipment is not due to safety or efficacy concerns. Ferring
    is not aware of any evidence indicating that the changes in manufacturing process pose
    any risks to patients. Ferring does not have an estimated time frame as to when they will
    resume shipping Menopur.
  - Menopur is indicated for the development of multiple follicles and pregnancy in ovulatory women as part of an assisted reproductive technology (ART) cycle.
- There are no other presentations of menotropins for injection available. Depending upon a patient's individual needs, other medications such as <u>chorionic gonadotropin</u>, <u>Pregnyl<sup>®</sup></u> (choriogonadotropin alfa), <u>Novarel<sup>®</sup></u> (chorionic gonadotrophin), <u>Ovidrel<sup>®</sup></u> (choriogonadotropin alfa), <u>Follistim<sup>®</sup> AQ</u> (follitropin alfa), <u>Gonal-F<sup>®</sup></u> (follitropin alfa), and <u>Gonal-F<sup>®</sup> RFF</u> (follitropin alfa) may be used as an alternative to Menopur.
  - Patients should contact their physician or health care provider if they have any questions regarding their Menopur therapy.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.